Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy
Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...
Viral hepatitis
AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China
AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new...
Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...
Sansure Biotech’s HBV RNA Detection Kit Receives NMPA Marketing Approval
Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...
Brii Biosciences’ HBV Drug Candidates Receive NMPA’s Breakthrough Therapy Designations
Brii Biosciences Ltd (HKG: 2137) has announced that two of its hepatitis B virus (HBV)...
Brii Biosciences’ BRII-835 Aims for Breakthrough Therapy Status in China for Chronic Hepatitis B
The Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...
Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B
Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...
Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal
Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI...
Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...
Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China
China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...
Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook
Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...
GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal
GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...
Fujian Cosunter Gains Ethical Approval for Phase IIa Study of GST-HG131 in Hepatitis B
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of ethical approval...
Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C
China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...
Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies
Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...
Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B
China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...
YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...
Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies
China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...